Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis-Reference-Cited by-同舟云学术

Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis

Published:2020-11 Issue: Volume:28 Page:100573
ISSN:2589-5370
Container-title:EClinicalMedicine
language:en
Short-container-title:EClinicalMedicine

Author:

Kanters Steve^ORCID,Vitoria Marco,Zoratti Michael,Doherty Meg,Penazzato Martina,Rangaraj Ajay,Ford Nathan,Thorlund Kristian,Anis Prof. Aslam H.,Karim Mohammad Ehsanul,Mofenson Lynne,Zash Rebecca,Calmy Alexandra,Kredo Tamara,Bansback Nick

Funder

World Health Organization

Publisher

Elsevier BV

Subject

General Medicine

Reference66 articles.

1. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection recommendations for a public health approach - Second edition. Geneva, Switzerland,2016

2. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis;Kanters;Lancet HIV,2016

3. When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank;Vitoria;Curr Opin HIV AIDS,2017

4. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings;Gilks;Lancet,2006

5. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda;Mills;Ann Intern Med,2011

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The safety of a dolutegravir (DTG)-based antiretroviral treatment (ART) regimen for pregnancy and birth outcomes in Ethiopia: evidence from multicenter cohort study;BMC Infectious Diseases;2024-09-02

2. Challenges in clinical monitoring of people with HIV: evolution from prediabetes mellitus to diabetes mellitus;AIDS;2024-08-29

3. “No One Needs to be Forced”: Qualitative Insights on Competing Priorities between Antiretroviral Therapy and Reproductive Health Planning during the Dolutegravir Rollout;AIDS and Behavior;2024-07-31

4. Modelling the impact of initiation delay, duration and prior PrEP usage on the prophylactic efficacy of FTC/TDF-containing post-exposure prophylaxis;2024-07-22

5. Challenges for Novel Antiretroviral Development in an Era of Widespread tenofovir-disoproxil/lamivudine (or emtricitabine)/dolutegravir availability (TLD) Availability;Clinical Infectious Diseases;2024-07-11